How does Aimovig work to prevent migraine?

Aimovig (erenumab-aooe) works to help prevent chronic migraine headaches by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks and rises during an attack.

The calcitonin gene-related peptide (CGRP) receptor antagonists are a new class of drugs for migraine. Aimovig, from Amgen, is also the first fully human monoclonal antibody for migraine prevention. This treatment for adults is given once-a-month by subcutaneous (under the skin) self-injections with an auto-injector type pen or a single-dose prefilled syringe.